Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Regenxbio partner with a major pharma for RGX-202 distribution by end of 2025?
Yes • 50%
No • 50%
Official announcements from Regenxbio or partner company
Regenxbio's RGX-202 Gene Therapy Shows Positive Results, FDA Approval Pathway Available
Nov 18, 2024, 12:34 PM
Regenxbio has reported promising results from its experimental gene therapy, RGX-202, for treating boys with Duchenne muscular dystrophy. The company presented clinical evidence showing improved muscle function in patients following the treatment. Regenxbio's CEO, Curran Simpson, indicated in an interview with STAT on Sunday that the FDA has communicated that the accelerated approval pathway remains available for this therapy. The positive data from a small trial is expected to support Regenxbio's pursuit of regulatory approval.
View original story
Yes • 50%
No • 50%
Pharmaceutical company • 25%
Biotechnology company • 25%
Academic institution • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
More than 50% • 25%
25% to 50% • 25%
10% to 25% • 25%
No Approval • 25%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%